Antisense Therapeutics Limited
ATHJF · OTC
6/30/2024 | 6/30/2023 | 6/30/2022 | 6/30/2021 | |
|---|---|---|---|---|
| Revenue | $2,968 | $1,580 | $1,778 | $578 |
| % Growth | 87.9% | -11.1% | 207.7% | – |
| Cost of Goods Sold | $62 | $95 | $89 | $103 |
| Gross Profit | $2,906 | $1,485 | $1,689 | $474 |
| % Margin | 97.9% | 94% | 95% | 82.1% |
| R&D Expenses | $10,699 | $10,162 | $4,535 | $4,913 |
| G&A Expenses | $552 | $3,054 | $2,921 | $3,556 |
| SG&A Expenses | $4,039 | $3,054 | $2,921 | $3,556 |
| Sales & Mktg Exp. | $1,376 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1,777 | $629 |
| Operating Expenses | $14,739 | $13,345 | $7,611 | $8,683 |
| Operating Income | -$11,833 | -$13,345 | -$7,611 | -$8,683 |
| % Margin | -398.6% | -844.7% | -428.1% | -1,502.9% |
| Other Income/Exp. Net | -$87 | -$95 | -$68 | -$58 |
| Pre-Tax Income | -$11,919 | -$11,380 | -$5,812 | -$8,061 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11,919 | -$11,380 | -$5,812 | -$8,061 |
| % Margin | -401.6% | -720.3% | -326.9% | -1,395.1% |
| EPS | -0.014 | -0.017 | -0.009 | -0.015 |
| % Growth | 20.6% | -84.8% | 38.3% | – |
| EPS Diluted | -0.014 | -0.017 | -0.009 | -0.015 |
| Weighted Avg Shares Out | 881,208 | 668,851 | 631,787 | 540,982 |
| Weighted Avg Shares Out Dil | 881,147 | 668,846 | 634,294 | 540,980 |
| Supplemental Information | – | – | – | – |
| Interest Income | $615 | $385 | $34 | $4 |
| Interest Expense | $4 | $8 | $12 | $11 |
| Depreciation & Amortization | $12 | $95 | $89 | $103 |
| EBITDA | -$11,900 | -$11,368 | -$5,827 | -$8,100 |
| % Margin | -400.9% | -719.5% | -327.7% | -1,402% |